Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG777 in Adults With Mild-to-Moderate Asthma
NCT06920901Phase 1Active, not recruiting
- Sponsor
- Apogee Therapeutics
- Start
- Mar 2025
- Primary completion
- Sep 2026
- Modality
- IgG Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in asthma comparing APG777 with Placebo (2 arms). Primary endpoints: Treatment Emergent Adverse Events at 52 weeks, Abnormal Laboratory Findings at 52 weeks and 3 more. Started Mar 2025; status: active, not recruiting.
02
Drugs
apg777
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06920901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06920901.